PlpE Subunit Vaccine for Pasteurella multocida Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines against P. multocida, such as live-attenuated vaccines and bacterins, are ineffective against homologous and heterologous challenges and have limitations like reversion to virulence or inadequate protection against diverse serotypes, leading to ongoing outbreaks of fowl cholera and other diseases in domestic animals.

Innovation Solution

Development of a subunit vaccine using recombinant Pasteurella lipoprotein E (PlpE) as the active antigen, which provides cross-protective immunity against P. multocida infections in animals, including fowl cholera, hemorrhagic septicaemia, and atrophic rhinitis, without the adverse effects of forming fibrosarcoma.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If live-attenuated vaccines are used against P. multocida, then immunogenicity is improved, but safety deteriorates due to reversion to virulence

Engineering Contradiction:

Improveprotective efficacyVSAvoidreversion to virulence

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts only the essential antigenic components (PlpE lipoprotein) from the whole bacterial cell, creating a subunit vaccine that provides protection without the harmful live bacterial components that could revert to virulence

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The vaccine uses specifically selected surface-exposed outer membrane proteins (PlpE) that are locally concentrated at the protective interface, providing targeted immunogenicity without the need for whole-cell attenuation

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If bacterins are used against P. multocida, then safety is improved, but protective efficacy deteriorates against heterologous challenges

Engineering Contradiction:

ImprovesafetyVSAvoidprotective efficacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The PlpE subunit vaccine provides universal protection against multiple serotypes (A:1, A:3, A:4) by targeting conserved surface-exposed outer membrane protein structures that are shared across different P. multocida strains

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The invention changes the antigenic parameter from whole-cell components to specific surface-exposed outer membrane proteins, enabling cross-protection against heterologous serotypes while maintaining safety

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If traditional vaccines are used, then broad serotype coverage is improved, but adverse side effects worsen due to fibrosarcoma formation

Engineering Contradiction:

Improveserotype coverageVSAvoidfibrosarcoma formation

Core Design Contradiction:

Adaptability or versatilityVSObject-generated harmful factors

Solution Approach 1:

The invention extracts only the beneficial antigenic properties of PlpE while eliminating the harmful components that cause fibrosarcoma formation, creating a purified subunit vaccine

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The vaccine targets specifically the surface-exposed outer membrane protein PlpE, concentrating immunogenicity at the protective interface while excluding components that cause adverse tissue reactions

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS8084043B2Subunit vaccine of <i>Pasteurella multocida </i>in veterinary uses

Publication Date: 2011.12.27 NATIONAL CHUNG HSING UNIVERSITY

AI summary

The present invention declaims the use of Pasteurella lipoprotein E (PlpE) as a subunit vaccine and the use of vaccines containing PlpE to protect animals from diseases caused by P. multocida. The results of vaccination and challenge experiments showed that mice and chickens immunized with PlpE were completely protected animals from challenge infection with 101-103 LD50 of P. multocida and no adverse effect was observed.